Pilocytic astrocytoma (PA) is a World Health Organization grade I glioma that occurs most commonly in children and young adults. Specific genetic alterations have been described in PA, but the pathogenesis remains poorly understood. We studied microRNA (miRNA) alterations in a large cohort of patients with PA. A total of 43 PA, including 35 sporadic grade I PA, 4 neurofibromatosis-1 (NF1) -associated PA, and 4 PA with pilomyxoid features, as well as 5 nonneoplastic brain controls were examined. BRAF fusion status was assessed in most cases. RNA was examined using the Agilent Human miRNA Microarray V3 platform. Expression of miRNA subsets was validated using quantitative real-time PCR (qRT-PCR) with Taqman probes. Validation of predicted protein targets was performed on tissue microarrays with the use of immunohistochemistry. We identified a subset of miRNAs that were differentially expressed in pediatric PAs versus normal brain tissue: 13 miRNAs were underexpressed, and 20 miRNAs were overexpressed in tumors. Differences were validated by qRT-PCR in a subset, with mean fold change in tumor versus brain of -17 (miR-124), -15 (miR-129), and 19.8 (miR-21) . Searching for predicted protein targets in Targetscan, we identified a number of known and putative oncogenes that were predicted targets of miRNA sets relatively underexpressed in PA. Predicted targets with increased expression at the mRNA and/or protein level in PA included PBX3, METAP2, and NFIB. A unique miRNA profile exists in PA, compared with brain tissue. These miRNAs and their targets may play a role in the pathogenesis of PA.
Keywords: BRAF, glioma, microRNA, neurofibromatosis, pilocytic astrocytoma. P ilocytic astrocytoma (PA) is a World Health Organization (WHO) grade I neoplasm representing the most frequent primary glioma among children and young adults. Most PAs have an excellent outcome after gross total resection, particularly when they arise in accessible anatomic locations, such as the cerebellum. However, a subset may behave in a more aggressive fashion and clinically progress despite the use of conventional treatments. Histologic features associated with a more aggressive course include the presence of monomorphous pilomyxoid features (ie, pilomyxoid variant) 1 and anaplasia in the form of brisk mitotic activity with or without necrosis. 2 Recent studies have highlighted novel genetic alterations associated with PA. Tandem duplications of the BRAF kinase domain, leading to a BRAF:KIAA1549 fusion, are present in most PAs. 3 -10 A subset of tumors have other, usually mutually exclusive alterations, including RAF1 rearrangements, a FAM131B-BRAF fusion mediated by a small interstitial deletion, or small BRAF insertions. 10 -12 In addition, PA is the most frequent glioma in patients with neurofibromatosis type 1, 13 resulting from germline mutations in the NF1 gene and homozygous inactivation in associated tumors, leading to RAS activation. All these genetic alterations lead to downstream activation of the MAPK signaling pathway.
In recent years, an increasing role for noncoding small RNA (ie, microRNA) has been uncovered in carcinogenesis. Mature microRNAs are small, single-stranded RNA molecules that bind to regulatory sequences of key mRNAs, promoting their degradation and/or inhibiting translation. In the process of carcinogenesis, the upregulation of particular microRNAs may affect tumor suppressors, whereas downregulation may allow overexpression of oncoproteins, resulting in deregulation of cell proliferation and survival.
Several microRNAs have been shown to be involved in brain tumorigenesis, including miR-21, miR-7, miR-181a/ b, miR-221, and miR-222, 15 -19 and seem to regulate oncogenic signaling pathways in diffuse gliomas, such as glioblastoma. 20, 21 PTEN in particular is a key tumor suppressor gene frequently inactivated in diffusely infiltrating gliomas and may in fact be targeted, albeit not exclusively, by specific microRNAs, such as miR-21. 22 Because microRNAs may have .1 target, microRNA profiling may stratify biological and clinically relevant subgroups more accurately than conventional mRNA profiling. 23 Low-grade pediatric gliomas, such as PAs in particular, are attractive for microRNA study because they lack gross genomic alterations, 24 suggesting that undiscovered epigenetic and subtle genetic changes may contribute to their pathogenesis. In addition, microRNA profiling may lead to further, biology-based refinements in classifying histopathologically ambiguous low-grade gliomas that defy traditional classification schemes and may have prognostic or therapeutic significance.
Because of the low level of genetic instability observed in PAs, we hypothesized that epigenetic or posttranscriptional regulation may play an important role in their pathogenesis, as described in other low-grade neuroectodermal tumors, such as schwannomas. 25 -27 Some studies have also highlighted a possible role for microRNAs in pediatric brain tumors, 28, 29 including medulloblastoma and ependymoma. 30 A small number of PAs have also been tested for microRNA levels, which may be differentially expressed in this tumor type. 29 Furthermore, overexpression of specific microRNAs has been observed in papillary carcinoma of the thyroid, another tumor characterized by BRAF aberrations. 31 Identification of key microRNAs also provides a rationale for developing inhibitory RNA strategies for therapeutic purposes in patients with cancer. 32 In the current study, we investigated global microRNA expression in a large series of genetically characterized PAs, including various pathologic subtypes, followed by characterization of possible relevant biologic targets.
Methods

Patients and Tumor Samples
A total of 43 PAs were obtained from patients undergoing surgery at Johns Hopkins Hospital, New York University, or Mayo Clinic, including 35 sporadic WHO grade I PAs, 4 NF1-associated PAs, and 4 PAs with pilomyxoid features. All patients (except for 2) were ≤18 years of age at the time of surgery (median, 10 years). Nonneoplastic tissue controls included fetal cerebellum (n ¼ 1) and pediatric cerebellum (n ¼ 1) obtained by autopsy and cerebral cortex obtained during seizure surgery (n ¼ 2) or biopsy for a nonspecific neurologic disorder with gliosis (n ¼ 1). Nine additional autopsy-derived cerebellar tissue samples were included for quantitative real-time polymerase chain reaction (qRT-PCR) experiments.
Anatomic locations for tumor samples included optic pathways (n ¼ 10) and supratentorial (n ¼ 11) and infratentorial compartments (n ¼ 22). Most tumors were previously evaluated for BRAF alterations as part of a separate study and by PCR and sequencing as reported. 7 Tumors were classified as aggressive if they progressed significantly within a year despite conventional therapies or recurred after gross total resections. Five patients met these criteria. Patient and tumor data are summarized in Table 1 . All studies were approved by the Johns Hopkins, NYU, and Mayo Clinic Institutional Review Boards.
MicroRNA Profiling
Snap frozen fresh tumor tissue samples were used for the microRNA studies. Sample quality assessment and microarray analyses were performed at the Sidney Kimmel Comprehensive Cancer Center Microarray Core Facility at the Johns Hopkins University (Baltimore, MD). In brief, total RNA was isolated using miRNeasy Mini kits (Qiagen), followed by quality checks of both total RNA and small RNA with use of a 2100 Bioanalyzer and software that detects 28S and 18S ribosomal RNA ratio, total RNA Integrity Number, and small RNA and miRNA concentrations in the total RNA isolated. Only samples with adequate total and microRNA were used in the study.
Samples were hybridized to a Human miRNA Microarray V3 kit (G4470C, Agilent Technologies) platform previously proven to produce reproducible results as described elsewhere. 33 This array contains 866 human and 89 human viral microRNAs from the Sanger database, version 12.0. (http://microrna. sanger.ac.uk/sequences/). Each miRNA species is printed 20 times with replicate probes on the array. Total RNA (150 ng) was first dephosphorylated with 11.2 units of calf intestine alkaline phosphatase at 378C for 30 min and followed by end-labeling with pCp-Cy3 (Agilent Technologies) and 15 units of T4 RNA ligase (GE Healthcare) at 168C for 2 h. Labeled samples were purified using Micro Bio-Spin 6 columns (Bio-Rad). Labeling efficiency and nucleic acid concentration were measured using Nanodrop 1000. Samples were then mixed with 10x blocking agent and 2x Hi-RPM hybridization buffer (Agilent Technologies), and hybridizations were performed at 558C with rotation at 20 rpm in a designated Agilent G2545A 
MicroRNA Data Analysis
Data normalization and analysis were performed using GeneSpring GX, version 11, according to the standard software recommendations (Agilent Technologies). In brief, miRNA signal intensities from GeneView files were subjected to quantile normalization. Expression differences were compared using the t test unpaired unequal variance (Welch) between pairs of interest. An adjusted P-value was obtained using the Benjamini-Hochberg false discover rate for multiple comparisons.
MicroRNA Validation
Validation of selected targets (mature miR-21, miR-124, mir-129) was performed using Taqman microRNA assays (Applied Biosystems) according to the manufacturer's recommendations. All samples were tested in triplicate using 96-well plates. The noncoding small nuclear RNA U6 was used as internal control. Wells lacking template were used as negative controls. Expression changes were compared by relative quantification in the form of fold changes obtained with the DDCt method. 34 
MicroRNA Target Prediction
Predicted mRNA targets for differentially expressed microRNAs were obtained from the TargetScan Human online database (release 6.0). With the use of this strategy, microRNA targets are predicted by matching the seed region of the specific microRNA with conserved 8mer and 7mer sites as described elsewhere 35 (http://www.targetscan.org).
Analysis of Functional Annotation Results
We tested the association between the lists of mRNA targets for differentially selected miRs and relevant cancer signaling pathways available from the NCI Pathway Commons database via analysis of functional annotation, as previously described. 36 In brief, the x 2 test was used to identify the specific signaling pathways significantly over-represented among the genes targeted by the microRNAs differentially expressed in PA. The Benjamini-Hochberg method was applied to correct the obtained P values for multiple testing, and a false discovery rate of ,5% was considered to be statistically significant.
Gene Expression Analysis
Differences in candidate mRNA targets were studied using data files obtained with Affymetrix HG-U133 Plus 2.0 chips. Sources included newly profiled 17 sporadic PAs (5 of which were also subjected to microRNA analysis) and 1 nonneoplastic cortex; 47 PA samples from our previously reported study 37 38 Tissue Microarray (TMA) and Immunohistochemistry Validation of protein targets was performed using 3 PAs and 1 diffuse glioma TMA containing 103 sporadic PAs, 17 NF1-associated PAs, 15 anaplastic PAs, and 79 diffuse gliomas of various grades. TMAs contained 3-4 cores per tumor. Immunohistochemical studies were performed using the following antibodies: PBX3 (Clone 1A11, LifeSpan BioSciences; 1:400), METAP2 (Rabbit polyclonal, Abnova; 1:50), and NFIB (Clone 2D6, LifeSpan BioSciences; 1:100). Immunohistochemical stains were scored by 2 independent observers (F.J.R. and C.H.) with use of the following semiquantitative scale that combined staining intensity and number of positive cells: 3 + (strong immunoreactivity in .50% tumor cells), 2 + (medium to weak immunoreactivity in 50% -100% of cells or strong immunoreactivity in 10% -50% tumor cells), 1 + (strong immunoreactivity in 1% -10% or medium to weak immunoreactivity in 10% -50% tumor cells), and 0 ¼ negative. For PBX3 and NFIB, only nuclear reactivity was considered to be significant, whereas only cytoplasmic METAP2 reactivity was scored. The x 2 or Fisher's exact test was used to compare proportions, and Student's t test or Wilcoxon rank sum was used to compare quantitative variables. All tests were 2-sided with P values ,.05 considered to be statistically significant.
Results
A Subset of microRNAs Is Differentially Expressed in Pediatric PAs
Comparisons were made between tumors and nonneoplastic brain, as well as different tumor subsets. The most robust differences were evident between tumors as a group and nonneoplastic brain tissues, as shown by unsupervised hierarchichal clustering (Fig. 1) . The volcano plot comparing tumor tissue and nonneoplastic brain using an adjusted P-value of.05 and fold change of 2 as cutoffs revealed 13 human microRNAs relatively underexpressed in tumors (Table 2 ) and 18 overexpressed (Table 3) (Fig. 2 ). Next, we tested a subset of Fig. 1 . A subset of microRNAs is differentially expressed between pilocytic astrocytomas (PAs) and nonneoplastic brain. Heatmap illustrates expression differences between PAs and nonneoplastic brain, as shown by hierarchical clustering. The nonneoplastic brain controls, representing cortex (C1-3), and fetal (C4) and pediatric cerebellum (C5) (box). Data were obtained using the Agilent miRNA Microarray V3 kit platform.
the cases (9 sporadic PA, 5 nonneoplastic brains) for hsa-miR-124, hsa-miR-129, and hsa-miR-21 with use of quantitative PCR. Mean miR-124 expression fold change in tumor versus brain was -17 (P ¼ .006), for miR-129 was -15 (P ¼ .009), and for miR-21 was 19.8 (P ¼ .003) (Fig. 3A-C) . Next, we expanded the control group to include 9 additional nonneoplastic cerebellar examples and also tested the 4 NF1-PAs. The lowest expression of miR-124 and miR-129 was actually present in the NF1-PA group, compared with sporadic PA and nonneoplastic brain, whereas the converse was true for miR-21 ( Fig. 3D -F) . These last differences were also present in the initial Agilent array profiling experiments (not shown).
Differentially Expressed MicroRNA in NF1-Associated Versus BRAF Fusion-Positive Tumors
We also searched for specific differences in hsa-microRNA expression among different PA groups, in particular, by anatomic location, pathologic subtype, genetic background, and clinical aggressiveness, although the differences were not as robust as between tumor and nonneoplastic brain. A volcano plot using an adjusted P value of .05 and fold change of 2 demonstrated 4 microRNAs differentially expressed between NF1-associated and tumors with BRAF alterations: hsa-miR-650 and hsa-miR-1276 were differentially overexpressed in NF1 tumors (3.7-fold), whereas hsa-miR-744* and hsa-miR-187* were underexpressed (2-and 2.5-fold). However, the overall expression levels of these microRNAs were relatively low, and further validation of miR-650 by qRT-PCR was noncontributory (data not shown). These findings suggest that expression differences between NF1-PA and sporadic PA may exist at the miRNA level in addition to the mRNA level as previously reported. 37 
Biologically Relevant MicroRNA Targets in PAs
We used the online program TargetScan to discover target mRNAs for microRNAs differentially expressed in PAs. A total of 36 mRNAs were predicted targets of ≥4 microRNAs differentially underexpressed in PAs, compared with brain, several encoding known, and putative oncoproteins (Table 4) , whereas 10 mRNAs were predicted targets for microRNAs differentially overexpressed in PAs (Table 5) . We searched for these predicted mRNAs in a combined dataset containing a total of 64 PA and 20 normal brain samples representing different anatomical regions. Most of these predicted targets were overexpressed in PA, compared with normal brain, and unsupervised clustering demonstrated clear separation between tumor and brain samples (Fig. 4) . Conversely, none of the mRNAs-predicted targets of overexpressed microRNAs in PA were underexpressed. When searching for genes differentially expressed in NF1 versus BRAF altered tumors, Targetscan search revealed 7 genes that were predicted targets of the overexpressed microRNAs (miR-650 and miR-1276) ( Table 6 ). There were no combined predicted targets of hsa-miR-744 and hsa-miR-187.
Next, we performed analysis of functional annotation to compare microRNA PA targets with signaling pathways. Of interest, many of the gene sets identified for 2 of the microRNAs with the lowest differential expression (miR-124 and miR-129 -5p) targeted multiple components of receptor tyrosine kinase/ MAPK/ERK signaling pathways (Supplementary  Tables 1 and 2) .
Because microRNAs may have a more important role in interfering with protein translation, we further tested candidate targets by immunohistochemistry with use of commercially available antibodies. From the cases studied for microRNA expression by qRT-PCR, paraffin sections were available for 5 tumors and 3 cerebral cortex controls. Most of these cases underexpressed A linear correlation between miR-124 and METAP2 was not observed (R 2 ¼ 0.006). Next, we searched for expression differences of these proteins in a large set of independent tumors obtained from 4 different microarrays. We identified strong (3+)PBX3 nuclear staining in most PAs, independent of subtype when compared with nonneoplastic brain and diffuse gliomas (P , .001) (Fig. 5) (Table 7) . Cytoplasmic METAP2 was expressed most strongly in NF1-associated PAs, compared with sporadic PAs (P , .001), and less so in sporadic examples, which in turn were mildly overexpressed, compared with diffuse gliomas and nonneoplastic brain (P ¼ .001) (Fig. 5 ) ( Table 7) . Strong (3+) nuclear NFIB labeling was also highest in anaplastic PAs, followed by sporadic PAs, compared with nonneoplastic brain and diffuse gliomas (P , .001). The k statistics comparing the scores from each observer were 0.25 (PBX3), 0.26 (NFIB), and 0.37 (METAP2), reflecting fair agreement on each. Of importance, the major differences between the groups were also reflected in the individual scores from each observer (data not shown).
Discussion
Numerous roles have been proposed and studied for microRNA in physiologic and pathologic states, including cancer. MicroRNA regulation has been a fruitful area of research in brain cancer, particularly glioblastoma. In fact, extensive post-transcriptional regulatory networks in this specific tumor type, in which microRNAs are key components, have emerged using bioinformatic and experimental approaches. 20 However, less is known about microRNA regulation of low-grade gliomas and PAs in particular. MicroRNA and mRNA profiling studies using 4 PA samples have demonstrated clustering for PAs separate from other pediatric brain tumors. 28, 29 In a study of WHO grade I -III astrocytomas, Li et al. identified a number of microRNAs to be underexpressed in all glioma grades, compared with brain, including miR-124, 21 which in our study, was also differentially underexpressed. miR-21 seems to target multiple components of key tumor suppressor and anti-apoptotic pathways, including p53, transforming growth factor beta, and mitochondria, 39 -42 as well as matrix metalloproteinases, which contribute to invasion in glioma. 43 Elevation of miR-21 has been found in a variety of tumor types, compared with normal tissues, and highlights the potential of microRNA to serve as glioma biomarkers (eg, in cerebrospinal fluid samples). 44 One important (but not exclusive) target of miR-21 is PTEN, a key suppressor of the PI3K/AKT/mTOR pathway. PTEN loss is a frequent molecular property of high-grade gliomas, and we have previously observed decreased levels in PAs with aggressive histologic features. 45 One of the main patterns identified in the current study is relative underexpression of a subset of microRNAs in PAs, compared with nonneoplastic brain, several of which may target known and putative oncogenes. MiR-124 is enriched in brain tissue, is downregulated in glioblastoma, and negatively affects glioblastoma proliferation and migration in vitro. 21, 46 Several miR-129 cluster members were underexpressed in PAs in our study. Other investigators have also found this microRNA to be underexpressed in pediatric brain tumors, including 4 PAs. 28 We also found increased gene expression and protein levels of putative oncogenes that may be important in the biology of PA and appeared to be targets of microRNA sets relatively underexpressed in PAs, compared with nonneoplastic brain. This is a novel aspect of our study, because these oncoproteins have not been associated with PA previously but may provide insights into low-grade glioma biology. Many oncoproteins in pediatric brain tumors play essential roles during central nervous system development. For example, PBX3 (pre-B cell leukemia homeobox 3) is one member of a group of PBX transcription factors belonging to the TALE (3 amino acid loop extension) homeobox gene family. They seem to play important developmental roles and affect gene signatures associated with cancers, particularly of hematolymphoid origin. In the nervous system, PBX3 is expressed in many anatomical regions during development, including areas of the medulla oblongata responsible for respiration control. 47 In fact, Pbx3 null mice die from central respiratory failure. 47 Pbx3 also seems to be important in the development of a subset of glutaminergic neurons in the developing dorsal horn of the spinal cord in murine studies 48 and the striatum and intercalated cell masses of the amygdala in monkey and rat. 49, 50 Recent studies have described post-transcriptional regulation of PBX3 in cancer, particularly by microRNAs. Downregulation of miR-181a and upregulation of a gene expression signature that includes PBX3 was associated with an adverse outcome in cytogenetically abnormal acute myeloid leukemia. 51 However, PBX3 has been found to also play a role in nonlymphoid malignancies, including prostate cancer, in which it may be regulated by a different microRNA (eg, Let 7d) in response to androgen. 52 In the current study, we identified underexpression of miR-181a and increased PBX3 mRNA and protein levels in PAs, compared with normal brain. Furthermore, PBX3 nuclear staining was higher in PAs, compared with diffuse gliomas, which raises the possibility that PBX3 may play a relatively specific role in PAs, compared with other gliomas. However, this finding will require further confirmation by alternative methods, functional experiments, and independent samples in the future.
In the current study, a subset of underexpressed microRNAs also had methionine aminopeptidase 2 (METAP2) as a predicted target. METAP2 functions include facilitation of protein translation, 53 probably by protecting eukaryotic initiation factor 2 from inhibition by phosphorylation. 54 When evaluating protein levels by immunohistochemistry, the highest levels were present in NF1-associated PAs, with a more modest elevation in some sporadic PAs. Of relevance to our study, METAP2 was identified to be elevated in the cerebrospinal fluid of mice with optic gliomas and NF1-associated PAs in human and murine optic glioma tissue. 54 In the same study, METAP2 was not overexpressed in Tsc1-deficient mouse brains or TSC-associated tumors, nor was it overexpressed in the small number of sporadic PA examined; therefore, increased levels were a consequence of neurofibromin loss and a property of NF1-associated tumors. METAP2 represents an attractive therapeutic target, because it is inactivated by fumagillin, a known fungal toxin. 55 METAP2 mRNA and/or protein overexpression has been reported in several cancers, including cholangiocarcinoma, 56 colorectal carcinoma, 57 and mesothelioma. 58 Fumagillin also inhibits hepatocellular carcinoma growth in vivo, 59 and pharmacologic inhibition of METAP2 also inhibits melanoma growth. 60 Another predicted target of a subset of underexpressed microRNAs with increased mRNA and protein levels in PAs was NFIB. NFIB, a CCAAT box-binding transcription factor, has been implicated as an oncogene in other tumors, being amplified in small cell carcinoma of the lung, 61 is overexpressed in breast cancer subsets, 62 and is involved in a novel fusion in salivary gland tumors and adenoid cystic carcinoma of the breast. 63, 64 In addition, NFIB was functionally validated as a target of miR-124, with a number of proteins being downregulated by miR-124 introduction in cultured HeLa cells at the protein and mRNA level, including NFIB. 65 Of interest, we saw an inverse correlation between miR-124 and NFIB extent of expression in the limited number of cases tested (5 S-PA and 3 brain controls).
Our results highlight the complementary value of microRNA profiling in the identification of biologically relevant targets in pediatric low-grade glioma. The most notable differences were between PA tumors and pediatric brain tissues. As a cautionary note, for the initial profiling experiments, 3 (of 5) of the nonneoplastic brain samples were obtained from cortex, and most PA arise in the cerebellum or in the optic pathways. We did find the same microRNA expression differences in additional cerebellar samples by qRT-PCR; unfortunately, we were unable to test optic pathway normal samples because of the difficulties in obtaining them as normal controls.
Modest differences between different tumor subsets, by location and histologic and molecular subtypes, were also observed but to a lesser extent. By looking at combined fold change differences and statistical significance, a subset of microRNAs was differentially expressed in NF1-associated PA, compared with tumors with BRAF alterations. In addition, the expression differences for miR-21, miR-124, and miR-129 that were subsequently validated by qRT-PCR were more conspicuous in the NF1-PA group. However, because of the relatively small number (4 tumors) tested in this study, the findings must be interpreted with caution and must be validated in the future in larger tumor datasets.
Prior mRNA gene expression studies have identified clear molecular differences in PAs by anatomic site and NF1 status 37, 66 and specific transcriptional regulatory networks for PA. 67 Of note, in a recent study, repressed 
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expression of ONECUT2 was part of a PA-specific transcriptional network, 67 and we identified it as a predicted target of 2 microRNAs differentially overexpressed in NF1-associated PA.
Our study has revealed some novel, putative oncogene targets that may be specifically upregulated in PA, compared with brain and diffuse gliomas. However, it is possible that specific microRNAs in PA may be regulated by (or regulate) canonical pathways that have been validated to play key roles in PA biology. One such pathway is MAPK, which is constitutively activated in the vast majority of PA by rearrangements and/or mutations involving BRAF and its family members. 3, 5, 6, 8, 9, 12 Of interest, miR-21 is up-regulated by increased MAPK activity in breast cancer 68 and in v-Ki-ras transformed NIH3T3 (DT) cells (compared with nontransformed NIH3T3 cells) 69 and, therefore, acts as a downstream effector in this pathway. As mentioned above, miR-124 is enriched in brain and is evolutionarily conserved even in other species, including snails. In a study focusing on the marine snail Aplysia, serotonin downregulated miR-124, an effect that is abolished by MAPK inhibition, 70 suggesting that MAPK is a negative regulator of miR-124. Of interest, through our analysis of functional annotation analysis, we found multiple sets of receptor tyrosine kinase/MAPK/ERK signaling components as possible targets. Collectively, these prior observations and our findings raise the intriguing possibility that MAPK pathway activation leads to alterations in key microRNA levels and that these microRNAs may be important downstream mediators of the pathway in PA and may regulate pathway components. This interesting possibility merits further study.
In summary, we have identified molecular differences based on microRNA expression levels in a large cohort of pediatric PAs, compared with human brain samples. Some investigators have highlighted current limitations in microRNA profiling in pediatric brain tumors, 29 which may require platforms with larger microRNA coverage and increased samples sizes. However, in the current study, we showed the feasibility in profiling as a novel approach to identify relevant targets in PA. Furthermore, we have identified increases in protein levels of putative oncogenes that may be of relevance to PA biology. At the present time, suitable in vivo or in vitro models to follow these observations are lacking but may become available in the near future. Additional studies are needed to confirm our findings and to address the possible functional consequences and clinical relevance for pathologic diagnosis and treatment of patients with PA.
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